Key points are not available for this paper at this time.
Design
Editorial
Discusses regulatory dilemmas and implications for approval and labeling of new chemical entities concerning drug-induced QT interval prolongation.
The views expressed in this paper are those of the author and do not necessarily represent the views or the opinions of Medicines Control Agency, other regulatory authorities or any of their advisory committees.
No takes yet. Share an insight, caveat, or question.
Rashmi R. Shah (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: